PlexusDx's Precision Peptide Genetic Test analyzes key variants like GIPR rs1800437 that influence how your body responds to tirzepatide and other peptide medications

Seek medical advice if you develop: Signs of severe dehydration : Persistent vomiting or diarrhoea, reduced urine output, dizziness, or confusion Symptoms of hypoglycaemia : Tremor, sweating, confusion, palpitations, or loss of consciousness, especially if taking insulin or sulphonylureas concurrently Allergic reactions : Rash, itching, swelling of the face or throat, or difficulty breathing Visual changes : Blurred vision or other eye problems, which may indicate diabetic retinopathy changes requiring ophthalmology review Symptoms of gallbladder disease : Right upper quadrant pain, jaundice (yellowing of skin or eyes), or fever Regarding bad breath specifically, consult your healthcare provider if halitosis: Persists despite good oral hygiene and hydration Is accompanied by other concerning symptoms such as unexplained weight loss (beyond expected therapeutic effect), fever, or persistent cough Significantly impacts your quality of life or social functioning Is associated with a sweet, fruity odour (which may indicate diabetic ketoacidosis, particularly in insulin-treated patients or those taking SGLT2 inhibitors concurrently) Regular monitoring is an integral part of tirzepatide therapy

What sets semaglutides apart is their remarkable ability to help individuals shed excess pounds while maintaining their overall health
NICE guidance recommends regular review of patients on GLP-1 receptor agonists to optimise outcomes and ensure treatment remains appropriate and well-tolerated
This safety overview does not replace Patient Drug Education or official prescribing information
3 Results 3.1 Semaglutide inhibits ferroptosis in HL-1 cells in a H/R model A H/R scenario was established using the HL-1 cardiomyocyte line in order to evaluate the protective effect of semaglutide